Spruce Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SPRB Nasdaq 8731 http://www.sprucebiosciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Spruce Biosciences Inc

Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting - Apr 22nd, 2024 8:05 pm
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know - Mar 27th, 2024 4:00 pm
Revenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB) - Mar 23rd, 2024 12:47 pm
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why - Mar 21st, 2024 2:20 pm
Spruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target Price - Mar 16th, 2024 12:59 pm
Spruce Biosciences Inc (SPRB) Reports Full Year 2023 Financial Results Amid Clinical Trial Setbacks - Mar 13th, 2024 9:33 pm
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates - Mar 13th, 2024 8:08 pm
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH - Mar 13th, 2024 8:01 pm
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference - Jan 30th, 2024 9:05 pm
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia - Jan 22nd, 2024 1:00 pm
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH - Jan 5th, 2024 1:00 pm
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024 - Jan 4th, 2024 1:00 pm
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates - Nov 13th, 2023 9:05 pm
Spruce Biosciences to Participate in the Jefferies London Healthcare Conference - Nov 2nd, 2023 8:05 pm
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia - Oct 18th, 2023 12:00 pm
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - Aug 28th, 2023 8:00 pm
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates - Aug 14th, 2023 8:00 pm
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why - Jul 24th, 2023 4:00 pm
Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023) - Jun 12th, 2023 8:00 pm
Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors - May 25th, 2023 12:00 pm